Drug Profile
BMX 010
Alternative Names: BMX 010; MnTE-2-PyPLatest Information Update: 01 Dec 2022
Price :
$50
*
At a glance
- Originator Duke University
- Developer BioMimetix
- Class Anti-inflammatories; Antiacnes; Antipruritics; Antipsoriatics; Metalloporphyrins; Skin disorder therapies; Small molecules
- Mechanism of Action NF E2 related factor 2 stimulants; NF-kappa B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Atopic dermatitis; Plaque psoriasis; Pruritus; Rosacea
- Discontinued Acne vulgaris
Most Recent Events
- 08 Nov 2022 BioMimetix initiates a phase II trial for Atopic dermatitis in USA (Topical, Ointment) (NCT05491447)
- 28 Sep 2022 BioMimetix suspended a phase-II clinical trial in Rosacea in USA (Topical, Cream) (NCT03756389)
- 08 Aug 2022 BioMimetix plans a phase II trial for Atopic dermatitis in October 2022 (Topical) (NCT05491447 )